Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Sponsor: Eli Lilly and Company
Listed as NCT04874636, this PHASE2 trial focuses on Chronic Low-back Pain and remains completed. Sponsored by Eli Lilly and Company, it has been updated 13 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Dec 2023 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Apr 2022 — Mar 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .